DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

DERMABOND (cyanoacrylate tissue
adhesive), 1790
Dermatitis
allergic contact, glucocorticoids for,
1809
atopic
azathioprine for, 1820–1821
calcineurin inhibitors for, 1822
cyclosporine for, 1821
IVIG for, 1827
mycophenolate mofetil for, 1823
photochemotherapy for, 1814
pimecrolimus for, 1822
chronic actinic, azathioprine for,
1820–1821
perioral, treatment of, 1816
treatment of, H 1
-receptor antagonists
for, 922
warfarin-induced, 864
Dermatitis herpetiformis, dapsone for,
1823
Dermatofibrosarcoma protuberans,
1732, 1734
Dermatology. See also Topical
application of drugs
alkylating agents in, 1821
anti-inflammatory agents in,
1822–1824
antimalarial agents in, 1819
biological agents in, 1824–1827,
1825t
calcineurin inhibitors in, 1821–1822
cytotoxic agents in, 1820–1822
dapsone in, 1823–1824
glucocorticoids in, topical, 1225t
imiquimod in, 1823
immunosuppressive agents in,
1820–1822
intralesional drug administration in,
1806
intravenous immunoglobulins in,
1827
photochemotherapy in, 1813–1815,
1814t
retinoids in, 1809–1812
sunscreens in, 1827–1828
systemic drug administration in,
1806
thalidomide in, 1824
vinblastine in, 1823
vitamin analogs in, 1812–1813
Dermatomyositis
azathioprine for, 1820–1821
cutaneous, antimalarials for, 1819
methotrexate for, 1820
Dermatomyositis (Cont.):
methylprednisolone sodium
succinate for, 1809
Dermis
blood vessels, 1804, 1804f
lymphatics, 1804, 1804f
structure of, 1804, 1804f
DES. See Diethylstilbestrol (DES)
Descemet’s membrane, 1774–1775
Descending thin limb (DTL), 673
Desensitization, 67–68
Desflurane
carbon monoxide and, 550
clinical uses of, 549
pharmacokinetics of, 549
side effects of, 549–550
cardiovascular, 549
gastrointestinal, 550
hepatic, 550
muscular, 550
neurological, 550
renal, 550
respiratory, 549–550
Desipramine
disposition of, 409t
dose and dosage forms of, 400t
potencies
at human transporters for
monamine neurotransmitters,
406t
at neurotransmitter receptors,
410t
side effects of, 400t
Desirudin, 859
Desloratadine, 920, 922t, 924, 1816
as metabolite of loratadine, 1802
pharmacokinetics of, 1816t
Deslorelin, 1119t
structure of, 1764t
Desmopressin acetate (DDAVP), 709t,
712–714
DESOGEN (ethinyl estradiol/
desogestrel),1835t
Desonide, cream, 1225t
DESOWEN (desonide), 1225t
Desoximetasone
cream, 1225t
ointment, 1225t
Desvenlafaxine, pharmacokinetics of,
1898t
Development
estrogen and, 1165–1166
placental transfer of drugs
and, 25
thyroid hormone and, 1139–1140
Development of drugs
attrition in, 8f
chemical libraries in, 4
cost of, 14f
“drugability” in, 6
economic viability in, 6
FDA’s role in, 7–10
hight-throughput screening in, 4
intellectual property and, 12
large molecules in, 5
metabolism and, 123, 142
nuclear magnetic resonance
spectroscopy in, 5
patents and, 12
pharmacogenetics and, 163–164
phases of, 8f
preclinical research in, 6–7
pricing and, 11
small molecules in, 4
time lines in, 8f
toxicity testing in, 6–7
X-ray crystallography in, 5
Dexamethasone
in cancer chemotherapy, 1755
relative potencies and equivalent
doses of, 1216t
therapeutic uses of, as antinausea
agent, in cancer
chemotherapy, 1344t
Dexamethasone sodium phosphate,
cream, 1225t
Dexmethylphenidate, 299–300
Dextroamphetamine, pharmacokinetics
of, 1830t
Dextromethorphan, 516
metabolism of, 128t
pharmacogenetics of, 151
polymorphisms and response to,
159t
DFP. See Diisopropyl
phosphorofluoridate (DFP)
DIABETA (glyburide), 1257t
Diabetes insipidus
central, 710–711
nephrogenic, 711
vasopressin and, 710–711
Diabetes mellitus (DM)
in adolescents, 1255
beta cell function in, 1246
in children, 1255
complications of, 1248–1249
diagnosis of, 1244–1256
emerging therapies for, 1267–1270
epidemiology of, 1248
forms of, 1245t
2017
INDEX